title: Treatment of diabetic maculopathy.
abstract: Diabetic maculopathy is an important cause of severe sight impairment. There has been a significant evolution in its treatment over the past decade and laser treatment is now largely being superseded by intravitreal injections of anti-vascular endothelial growth factor agents or corticosteroids.
authors.affiliation: FY1 in the Department of Medicine, Imperial College Healthcare NHS Trust, London.
authors.forename: Gemma S L
authors.initials: GS
authors.lastname: Manasseh
authors.forename: Emily Han
authors.initials: EH
authors.lastname: Shao
authors.forename: Simon R J
authors.initials: SR
authors.lastname: Taylor
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000628:therapy*; D005654:Fundus Oculi; D006801:Humans; D017075:Laser Coagulation / Q000379:methods*; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000175:diagnosis / Q000628:therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A